Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma

NCT06014086 is registered in ClinicalTrials.gov with Phio Pharmaceuticals Inc. as lead sponsor.

NCT NCT06014086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06014086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma
Lead sponsor
Phio Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2023
Completion date
March 17, 2026
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma of skin, merkel cell carcinoma of skin, squamous cell carcinoma of the skin